Inamed Stresses Hylaform Non-Inferiority; EU Clears Silicone Implant Safety
This article was originally published in The Gray Sheet
Executive Summary
FDA's regulation of Genzyme's hyaluronic acid-based Synvisc osteoarthritic knee pain treatment could offer a precedent for labeling of the firm's Hylaform HA dermal filler